miR‑186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis

  • Authors:
    • Qianren Xiao
    • Zhihui Wei
    • Yunyun Li
    • Xin Zhou
    • Jiajun Chen
    • Tengyu Wang
    • Gaohai Shao
    • Minghua Zhang
    • Zhongzu Zhang
  • View Affiliations

  • Published online on: April 23, 2018     https://doi.org/10.3892/or.2018.6394
  • Pages: 2703-2710
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is the most common primary bone malignancy among children and adolescents. Deregulation of microRNAs has been well documented in OS, while the putative effects of miR‑186 have not been identified yet. In the present study, we assessed the expression of miR‑186 in a cohort of 40 OS tissues and explored its effects on OS cells. As expected, miR‑186 was suppressed in OS tissues compared with relative normal tissues. Overexpression of miR‑186 inhibited cell proliferation, arrested the cell cycle progression and suppressed the cell invasion of the HOS and U2 OS cell lines. These results indicated the tumor‑suppressive role of miR‑186 in OS. Among the target genes of miR‑186, we found that pituitary tumor transforming gene 1 (PTTG1) may be a target gene of miR‑186 in OS and that the overexpression of PTTG1 could partially abolish miR‑186‑mediated suppressive effects on OS cells. Aerobic glycolysis is the major way of energy supply and is one of the characteristic phenotypes of tumor cells. In addition, we found that overexpression of miR‑186 significantly suppressed the expression of hypoxia‑inducible factor 1 (HIF‑1) and inhibited the glucose uptake and lactate production of OS cells. Collectively, our findings demonstrated that miR‑186 functions as a tumor suppressor in OS cells partially by targeting PTTG1 and that HIF‑1‑mediated suppression of aerobic glycolysis may be also involved in its suppressive effects.

References

1 

Olivieri F, Capri M, Bonafè M, Morsiani C, Jung HJ, Spazzafumo L, Viña J and Suh Y: Circulating miRNAs and miRNA shuttles as biomarkers: Perspective trajectories of healthy and unhealthy aging. Mech Ageing Dev. 165:162–170. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, Shen Y and Huang TT: Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics. 45:1206–1214. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Kim HJ, Chalmers PN and Morris CD: Pediatric osteogenic sarcoma. Curr Opin Pediatr. 22:61–66. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Kumar Ram RM, Boro A and Fuchs B: Involvement and clinical aspects of MicroRNA in osteosarcoma. Int J Mol Sci. 17:E8772016. View Article : Google Scholar : PubMed/NCBI

5 

Geng S, Gu L, Ju F, Zhang H, Wang Y, Tang H, Bi Z and Yang C: MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med. 20:1611–1619. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Xiao Q, Huang L, Zhang Z, Chen X, Luo J, Zhang Z, Chen S, Shu Y, Han Z and Cao K: Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4. Oncol Res. 25:267–275. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Ye J, Zhang Z, Sun L, Fang Y, Xu X and Zhou G: miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst. 12:3417–3424. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Lei GS, Kline HL, Lee CH, Wilkes DS and Zhang C: Regulation of collagen V expression and epithelial-mesenchymal transition by miR-185 and miR-186 during idiopathic pulmonary fibrosis. Am J Pathol. 186:2310–2316. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Ando K, Heymann MF, Stresing V, Mori K, Rédini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Cai SQ, Dou TT, Li W, Li SQ, Chen JQ, Zhou J, Zheng M and Man XY: Involvement of pituitary tumor transforming gene 1 in psoriasis, seborrheic keratosis, and skin tumors. Discov Med. 18:289–299. 2014.PubMed/NCBI

11 

Yu R, Heaney AP, Lu W, Chen J and Melmed S: Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem. 275:36502–36505. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Liu L, Wang Y, Bai R, Yang K and Tian Z: miR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1alpha regulation. Oncogenesis. 6:e3182017. View Article : Google Scholar : PubMed/NCBI

13 

Yu R, Ren SG, Horwitz GA, Wang Z and Melmed S: Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging. Mol Endocrinol. 14:1137–1146. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Antoniou A, Mastroyiannopoulos NP, Uney JB and Phylactou LA: miR-186 inhibits muscle cell differentiation through myogenin regulation. J Biol Chem. 289:3923–3935. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Cao C, Sun D, Zhang L and Song L: miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1. Oncotarget. 7:79956–7996. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, Radmark O, Giachetti A and Ziche M: Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and −186 expression: Novel mechanism of VEGF modulation in prostate cancer. Oncotarget. 7:44350–44364. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Koh MY, Spivak-Kroizman TR and Powis G: HIF-1alpha and cancer therapy. Recent Results Cancer Res. 180:15–34. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Masoud GN and Li W: HIF-1alpha pathway: Role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, Giamarellos-Bourboulis EJ, Martens JH, Rao NA, Aghajanirefah A, et al: mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 345:12506842014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2018
Volume 39 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xiao, Q., Wei, Z., Li, Y., Zhou, X., Chen, J., Wang, T. ... Zhang, Z. (2018). miR‑186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis. Oncology Reports, 39, 2703-2710. https://doi.org/10.3892/or.2018.6394
MLA
Xiao, Q., Wei, Z., Li, Y., Zhou, X., Chen, J., Wang, T., Shao, G., Zhang, M., Zhang, Z."miR‑186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis". Oncology Reports 39.6 (2018): 2703-2710.
Chicago
Xiao, Q., Wei, Z., Li, Y., Zhou, X., Chen, J., Wang, T., Shao, G., Zhang, M., Zhang, Z."miR‑186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis". Oncology Reports 39, no. 6 (2018): 2703-2710. https://doi.org/10.3892/or.2018.6394